Two Sigma Advisers
GLMD icon

Two Sigma Advisers’s Galmed Pharmaceuticals GLMD Stock Holding History

Two Sigma Advisers’s Portfolio GLMD Stock Details GLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,936
Closed -$23.6K – 875
2025
Q4 		$23.6K Buy
+3,936
New +$36.8K ﹤0.01% 2308
2024
Q2 		– Sell
-232
Closed -$7.71K – 2533
2024
Q1 		$7.71K Sell
232
-231
-50% -$8.33K ﹤0.01% 2421
2023
Q4 		$20.2K Sell
463
-64
-12% -$2.44K ﹤0.01% 2450
2023
Q3 		$31.4K Buy
+527
New +$55.9K ﹤0.01% 2304
2021
Q3 		– Sell
-11
Closed -$46K – 2519
2021
Q2 		$46K Sell
11
-1
-8% -$4.35K ﹤0.01% 2386
2021
Q1 		$60K Buy
+12
New +$66.4K ﹤0.01% 2488

Other funds holding GLMD

Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Two Sigma Advisers's GLMD Position: Q1 2026 in Review

Two Sigma Advisers sold out of Galmed Pharmaceuticals (GLMD) in Q1 2026, closing a stake of 3,936 shares — an estimated $23.6K sold.

Two Sigma Advisers first reported a position in GLMD in Q1 2021 and held it in 6 quarters. The position peaked at $60K in Q1 2021. 13 funds tracked by Wall St. Rank hold GLMD as of Q1 2026.

  • Two Sigma Advisers reported no remaining Galmed Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 3,936 Galmed Pharmaceuticals shares in Q1 2026, an estimated $23.6K.
  • Two Sigma Advisers first reported a position in Galmed Pharmaceuticals in Q1 2021 and held it in 6 quarters.
  • Two Sigma Advisers's Galmed Pharmaceuticals position peaked at $60K in Q1 2021.
  • 13 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.